Arabic Arabic English English French French German German
dark

Eagle Pharmaceuticals Announces TREAKISYM (bendamustine) Ready-to-Dilute (“RTD”) Formulation

-Eagle believes new indication could allow for a significant expansion of the overall market opportunity-

-RTD and Rapid Infusion (“RI”) formulations anticipated to generate approximately $25 million of combined royalty and milestone revenue at peak- Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Legend Biotech Announces Submission of European Marketing Authorisation Application for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Next Post

Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial

Related Posts
Total
0
Share